Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor

Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.

$4 billion
Takeda will pay $4bn for Nimbus's Phase IIb TYK2 inhibitor • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. will go after Bristol Myers Squibb Company and its recently approved oral TYK2 inhibitor Sotyktu for moderate-to-severe psoriasis, agreeing on 13 December to pay Nimbus Therapeutics, Inc. an eye-opening $4bn up front for a Phase IIb asset from the same class, NDI034858, with plans to take it into Phase III in psoriasis next year and potentially a host of other autoimmune indications down the road.

The deal continues a string of lucrative deals for in-house discovered assets by privately held Nimbus, which focuses on computational...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.